Results 151 to 160 of about 66,016 (261)

From Platelet Toxicity to Precision Targeting: Evolving Strategies to Overcome Thrombocytopenia in BCL-2/BCL-XL Inhibition. [PDF]

Health Sci Rep
Mohiuddin M.
europepmc   +1 more source

Optical genome mapping improves detection and characterisation of cytogenetic abnormalities in non‐Hodgkin lymphomas

British Journal of Haematology, EarlyView.
Optical genome mapping (OGM) is feasible on fresh and frozen tissue lymphoma samples and demonstrated its added value for accurate diagnostic classification. OGM surpasses karyotype and FISH in refining diagnoses of lymphoma, identifying class‐defining rearrangements along with prognostic markers.
Coura Fall, Agnès Daudignon, Séverine Valmary‐Degano, Julie Mondet, Lucile Bussot, Lysiane Molina, Simon Chevalier, Edouard Bonneville, Pierre Aubert, Sylvie Tondeur, Clémentine Legrand, Jean‐Baptiste Gaillard, Hélène Guermouche, Anouk Emadali, Sylvain Carras, Christine Lefebvre   +15 more
wiley   +1 more source

PRMT5 inhibition sensitizes B-cell lymphoma cells to ferroptosis. [PDF]

Leukemia
Liu Y, Chen R, Gao X, Zhu F, Ni Q, Bates PD, Wu S, Zai Z, Obernberger VA, Weerawardhene K, Tourdot TK, Petta S, Conyers MJ, Capitini CM, Rui L.   +14 more
europepmc   +1 more source

Impact of rituximab maintenance on survival in patients with mantle cell lymphoma: a population-based cohort study. [PDF]

Blood Adv
Stedema F, Brink M, Huisman F, van Rijn R, Sijs-Szabo A, Nijhof I, Diepstra A, Vergote V, van Gorkum G, Flinsenberg T, Huls G, van Meerten T, Doorduijn J, Plattel W, Nijland M.   +14 more
europepmc   +1 more source

Comparative atrial fibrillation risk across Bruton's tyrosine kinase inhibitors in B‐cell malignancies: A nationwide population‐based study

British Journal of Haematology, EarlyView.
Real‐world nationwide data in B‐cell malignancies reveal a markedly increased 1‐year incidence of hospitalized atrial fibrillation with ibrutinib compared with second‐generation Bruton's tyrosine kinase inhibitors and venetoclax, arguing for closer cardiac surveillance.
Yoann Zelmat, Loic Ysebaert, Paul Gautier, Agnes Sommet, Margaux Lafaurie, Fabien Despas   +5 more
wiley   +1 more source

Dissecting minimal residual disease dynamics to improve outcome prediction in mantle cell lymphoma: Data from the Fondazione Italiana Linfomi (FIL)-MCL0208 clinical trial. [PDF]

Hemasphere
Cordero F, Ferrero S, Pernice S, Genuardi E, Volpatto D, Sirovich R, Civita AM, Evangelista A, Ragaini S, Di Rocco A, Re A, Stefoni V, Cavallo F, Boccomini C, Balzarotti M, Zilioli VR, Gomes da Silva M, Arcaini L, Celli M, Zaccaria GM, Tortarolo D, Beccuti M, Hoster E, Pott C, Macintyre E, Hermine O, Dreyling M, Ladetto M.   +27 more
europepmc   +1 more source

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

British Journal of Pharmacology, EarlyView.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source

Evolving therapeutic strategies in mantle cell lymphoma: advancements and future directions. [PDF]

Leukemia
Tavarozzi R, Maher N, Catania G, Zacchi G, D'Andrea F, Sofia A, Zanni M, Ladetto M.   +7 more
europepmc   +1 more source

The Natural Quassinoid Brusatol Enhances Venetoclax Efficacy and Overcomes Resistance in Myeloid Leukemias

Cancer Science, EarlyView.
Schematic illustration of the mechanisms by which the natural quassinoid brusatol induces apoptosis in myeloid leukemias and enhances venetoclax efficacy via p53‐dependent apoptosis and mitochondrial dysfunction. ABSTRACT While venetoclax‐based combinations have shown promising results in acute myeloid leukemia (AML), the remission duration is ...
Shin‐ichiro Kawaguchi, Kazuya Sato, Junko Izawa, Norihito Takayama, Hiroko Hayakawa, Ken Suzaki, Susumu Goyama, Chiyoko Kato, Eiji Sakashita, Kaoru Tominaga, Hitoshi Endo, Yoshinobu Kanda   +11 more
wiley   +1 more source

Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Mantle Cell Lymphoma: Real-World Outcomes, Late Relapse Patterns, and Clinical Utility in the Chimeric Antigen Receptor T-Cell Era. [PDF]

EJHaem
Aydilek E, Mazzeo P, Hasenkamp J, Maulhardt M, Tix T, Shumilov E, Wulf G.   +6 more
europepmc   +1 more source